S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:HOWL

Werewolf Therapeutics - HOWL Stock Forecast, Price & News

$1.84
+0.01 (+0.55%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.80
$1.96
50-Day Range
$1.73
$5.02
52-Week Range
$1.63
$15.89
Volume
360,439 shs
Average Volume
81,763 shs
Market Capitalization
$56.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Werewolf Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
987.0% Upside
$20.00 Price Target
Short Interest
Healthy
1.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Werewolf Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.04) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

101st out of 1,047 stocks

Pharmaceutical Preparations Industry

39th out of 512 stocks

HOWL stock logo

About Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

H.C. Wainwright Remains a Buy on Werewolf Therapeutics (HOWL)
Who is Werewolf By Night?
HOWL Werewolf Therapeutics, Inc.
See More Headlines
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Company Calendar

Last Earnings
11/10/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+987.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-49,980,000.00
Pretax Margin
-655.29%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.26 per share

Miscellaneous

Free Float
11,468,000
Market Cap
$56.58 million
Optionable
Not Optionable
Beta
-0.70

Key Executives

  • Dr. Daniel J. Hicklin Ph.D. (Age 58)
    Founder, CEO, Pres, Sec. & Director
    Comp: $762.87k
  • Mr. Timothy W. Trost CPA (Age 64)
    CFO, Treasurer & Assistant Sec.
    Comp: $511.88k
  • Dr. Chulani Karunatilake Ph.D.
    Chief Technology Officer
  • Dr. Reid Leonard Ph.D. (Age 63)
    Chief Operating Officer
  • Dr. Cynthia Seidel-Dugan Ph.D. (Age 63)
    Chief Scientific Officer
  • Dr. Randi Isaacs M.D. (Age 66)
    Chief Medical Officer
  • Ms. Ellen A. Lubman M.B.A. (Age 46)
    Chief Bus. Officer













HOWL Stock - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings
or view top-rated stocks.

What is Werewolf Therapeutics' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month target prices for Werewolf Therapeutics' stock. Their HOWL share price forecasts range from $20.00 to $20.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 987.0% from the stock's current price.
View analysts price targets for HOWL
or view top-rated stocks among Wall Street analysts.

How have HOWL shares performed in 2022?

Werewolf Therapeutics' stock was trading at $11.91 on January 1st, 2022. Since then, HOWL shares have decreased by 84.6% and is now trading at $1.84.
View the best growth stocks for 2022 here
.

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our HOWL earnings forecast
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) posted its earnings results on Thursday, November, 10th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.20. The company had revenue of $4.97 million for the quarter, compared to analyst estimates of $6.10 million.

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Werewolf Therapeutics' stock symbol?

Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include PFM Health Sciences LP (9.16%), Rubric Capital Management LP (3.27%), Laurion Capital Management LP (1.70%), Vanguard Group Inc. (1.42%), BlackRock Inc. (0.48%) and Ergoteles LLC (0.39%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Werewolf Therapeutics' stock price today?

One share of HOWL stock can currently be purchased for approximately $1.84.

How much money does Werewolf Therapeutics make?

Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $56.57 million. The company earns $-49,980,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

How can I contact Werewolf Therapeutics?

Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com.

This page (NASDAQ:HOWL) was last updated on 12/2/2022 by MarketBeat.com Staff